People: Sophiris Bio Inc (PTXRF.PK)

PTXRF.PK on OTC Markets Group - US Other OTC and Grey Market

0.27USD
17 May 2013
Price Change (% chg)

$0.00 (-0.19%)
Prev Close
$0.27
Open
$0.27
Day's High
$0.27
Day's Low
$0.27
Volume
1,000
Avg. Vol
9,394
52-wk High
$0.41
52-wk Low
$0.17

Search Stocks

Summary

Name Age Since Current Position

Lars Ekman

 62 2012 Executive Chairman of the Board

Randall Woods

 2012 President, Chief Executive Officer, Director

Peter Slover

 2013 Chief Financial Officer

Allison Hulme

 2011 Chief Operating Officer, Head - Research & Development

Iain Mant

 2007 Corporate Secretary

John Geltosky

 2008 Independent Director

James Heppell

 2003 Independent Director

Noah Knauf

 2012 Independent Director

William Rohn

 68 2011 Independent Director

Amit Sobti

 2011 Independent Director
» Insider Trading

Biographies

Name Description

Lars Ekman

 Dr. Lars Ekman, M.D., Ph.D., is Executive Chairman of the Board of Sophiris Bio Inc. He has been the Executive Chairman since April 2011 and a member of the Board since November 2010. He served as the President from April 2011 to August 2012. Dr. Ekman also currently serves as an executive partner of Sofinnova Ventures, a venture capital fund, a position he has held since April 2008. From January 2001 to December 2007, Dr. Ekman was Executive Vice President and President of Research & Development at Elan Pharmaceuticals, a neuroscience-focused biotechnology company. Prior to joining Elan, Dr. Ekman was Executive Vice President, Research and Development at Schwartz Pharma AG, a biopharmaceutical company, from February 1997 to January 2001. Prior to joining Schwartz, Dr. Ekman served in various senior executive roles at Pharmacia (now Pfizer), a pharmaceutical company, for over 16 years. Dr. Ekman is a director of Amarin Corporation plc, Elan Corporation Plc, InterMune Inc., and two private companies, Ocera Therapeutics, Inc. and Cebix Incorporated. Dr. Ekman is a board certified surgeon with a Ph.D. in experimental biology. He obtained his Ph.D. and M.D. from the University of Gothenburg, Sweden.

Randall Woods

 Mr. Randall E. Woods serves as President, Chief Executive Officer, Director of Sophiris Bio Inc. Mr. Woods has been the Chief Executive Officer and President since August 2012 and a member of the Board since October 2012 and brings with him 40 years of biotech and pharmaceutical leadership experience. Prior to joining Sophiris, Mr. Woods was serving as a consultant to a number of private biotechnology companies. From September 2007 until September 2011, Mr. Woods was President and Chief Executive Officer of Sequel Pharmaceuticals, a private biotechnology company. Mr. Woods was the President and Chief Executive Officer of NovaCardia, Inc., a pharmaceutical company focused on cardiovascular diseases, until its acquisition by Merck & Co. From May 1996 until July 2003 and prior to NovaCardia, Mr. Woods was President and Chief Executive Officer of Corvas International, Inc., a publicly held biopharmaceutical company focused on cardiovascular disease and cancer, until its acquisition by Dendreon Corporation in July 2003. Before joining Corvas, he served as President of Boehringer Mannheim’s U.S. pharmaceutical operations from March 1994 until March 1996 and was Vice President of marketing and sales at Boehringer Mannheim from December 1993 to February 1994. Prior to that he spent 20 years at Eli Lilly & Company, a pharmaceutical company, in various sales and marketing positions from 1973 to December 1993. Mr. Woods is a past Chairman for the advisory board of UC San Diego’s Sulpizio Family Cardiovascular Center and is a past Chairman of the Board of Directors for BIOCOM, a life science industry association in Southern California. Mr. Woods serves on the Board of Arena Pharmaceuticals and is Chairman of the Board for Sorbent Therapeutics. He received his B.S. in Biology and Chemistry from Ball State University and an MBA in Marketing from Western Michigan University.

Peter Slover

 Mr. Peter T. Slover is the Chief Financial Officer, Director of Sophiris Bio Inc., since January 2013. He served as the Head of Finance and Principal Accounting Officer from April 2012 to January 2013. From April 2004 to April 2012, Mr. Slover held a variety of management positions at Anadys Pharmaceuticals, Inc., a public biotechnology company, including Vice President, Finance and Operations, a position that he held from July 2009 to April 2012, Senior Director, Finance and Corporate Controller, Senior Manager, Financial Reporting and Internal Controls and Manager of Financial Reporting. Prior to joining Anadys, Mr. Slover was an auditor at KPMG LLP, where he spent seven years in public accounting. Mr. Slover is a Certified Public Accountant in the State of California. He received a B.S. degree in Business Administration from Shippensburg University.

Allison Hulme

 Dr. Allison J. Hulme, Ph.D., is Chief Operating Officer, Head - Research & Development of Sophiris Bio Inc. Dr. Hulme brings over 20 years of drug development experience to the company. From January 2005 to October 2009, Dr. Hulme served as Executive Vice President of Autoimmune, Tysabri, Global Development and Head of Autoimmune and Tysabri Franchise at Elan Corporation, plc (also known as Elan Pharmaceuticals), a neuroscience-focused biotechnology company. She served as Executive Vice President and head of global development at Elan Pharmaceuticals from October 1995 to January 2005. Previously, Dr. Hulme held several positions in clinical research at Glaxo Wellcome Pharmaceuticals and served as lecturer at Luton University. Dr. Hulme holds a first class honors Degree in Science from Luton University (University of Bedfordshire) and a Ph.D. from Cranfield Institute of Technology.

Iain Mant

 Mr. Iain R. Mant is Corporate Secretary of Sophiris Bio Inc. Mr. Mant is a partner with Fasken Martineau DuMoulin LLP and advises clients, including biotechnology clients, on venture capital financing, private placements, public equity and debt financings, mergers and acquisitions, and corporate governance matters. He holds a Bachelor of Commerce degree from the University of Alberta and an LLB from the University of Toronto.

John Geltosky

 Dr. John Geltosky, Ph.D., is an Independent Director of Sophiris Bio Inc., since September 29, 2008. He is currently Managing Director of JEG and Associates, LLC, a business development consultancy firm focused on biotech and pharmaceuticals, a position he has held since September 2011. From October 2007 to September 2011, Dr. Geltosky served as Senior Vice President of Business Development for Arizona Technology Enterprises, the technology transfer arm of Arizona State University. Prior to Arizona Technology Enterprises, Dr. Geltosky was Vice President of External Science, Technology and Licensing at Bristol Myers Squibb (“BMS”), a public pharmaceuticals company, where he was responsible for the acquisition and licensing of, as well as coordinating due diligence efforts on, potential in- and out-licensing candidates. Prior to joining BMS, Dr. Geltosky was President and Chief Executive Officer of Message Pharmaceuticals, Inc., a pharmaceutical company. Prior to Message Pharmaceuticals, he was Vice President, Scientific Licensing, Worldwide Business Development at SmithKline Beecham (now GlaxoSmithKline). For 10 years, Dr. Geltosky held roles of increasing responsibility within Johnson & Johnson. Dr. Geltosky began his career as a research scientist at E.I. DuPont. Dr. Geltosky holds a B.S. in chemistry from Memphis State University and a Ph.D. in biochemistry from the California Institute of Technology.

James Heppell

 Mr. James Heppell is an Independent Director of Sophiris Bio Inc., since May 20, 2003. Mr. Heppell was the founding Chief Executive Officer and President. He is President of B.C. Advantage Funds (VCC) Ltd., a venture capital corporation located in British Columbia, a position he has held since July 2005. Prior to his involvement with B.C. Advantage Funds, Mr. Heppell was cofounder, Chief Executive Officer and Fund Manager of the Advantage Life Science Fund I. Mr. Heppell is a director of B.C. Advantage Funds (VCC) Ltd. and Venturi Ventures Inc., a medical device firm, and Chairman or director of a number of private life science companies. Previously, Mr. Heppell was Chairman of Inovio Biomedical Corp., a public biotechnology company. Mr. Heppell has a B.Sc. degree in Microbiology and an LL.B. from the University of British Columbia.

Noah Knauf

 Mr. Noah J. Knauf has been appoonted as an Independent Director of Sophiris Bio Inc., since December 2012. He is currently an investment professional at Warburg Pincus LLC focusing on the healthcare sector, a position he has held since August 2007. From March 2003 to June 2005 Mr. Knauf was an Associate at Parthenon Capital, a private equity firm. Prior to joining Parthenon Capital, Mr. Knauf was an Associate Consultant with Bain & Company, a global consulting firm, from August 2001 to March 2003. Mr. Knauf currently serves on the Boards of Directors of Constitution Medical Investors, Home Dialysis Plus, International Technidyne Corporation, Keystone Dental, RegionalCare Hospital Partners and Silk Road Medical. Mr. Knauf holds an M.B.A. from Stanford University Graduate School of Business, where he was an Arjay Miller scholar, and a B.S.B.A. from the University of Arizona.

William Rohn

 Mr. William R. Rohn is an Independent Director of Sophiris Bio Inc., since February 22, 2011. He has over 35 years of experience as a senior executive in the pharmaceutical and biotech industry. Mr. Rohn retired in January of 2005 from the position of Chief Operating Officer at Biogen-Idec, a global biotechnology company. Prior to that position, Mr. Rohn was the President and chief operating officer of IDEC Pharmaceuticals, a biopharmaceutical company, from January 1999 to November 2003. Mr. Rohn spent approximately 25 years in the pharmaceutical sector in a variety of commercial operating roles of increasing responsibilities at Abbott Laboratories, Bristol-Myers Squibb Co. and Adria Laboratories (now part of Pfizer). Mr. Rohn serves on the board of directors of Cebix Incorporated and Hansen Medical, and was previously a director at Cerus Corp., Elan Corporation plc, Metabasis Therapeutics Inc. and Pharmacyclics, Inc. Mr. Rohn received a B.A. Degree in Marketing from Michigan State University.

Amit Sobti

 Mr. Amit Sobti is an Independent Director of Sophiris Bio Inc., since February 22, 2011. Since September 2004, he has worked at Warburg Pincus, a private equity firm, where he focuses on the healthcare sector and has been a principal since January 2011. Prior to joining Warburg Pincus in September 2004, he worked at Rhône Capital, a private equity firm, and at Merrill Lynch, in the Mergers & Acquisitions group. Mr. Sobti received a B.A. in Business Economics and a B.A. in Computer Science from Brown University.

Basic Compensation

Name Fiscal Year Total

Lars Ekman

 --

Randall Woods

 --

Peter Slover

 --

Allison Hulme

 --

Iain Mant

 --

John Geltosky

 --

James Heppell

 --

Noah Knauf

 --

William Rohn

 --

Amit Sobti

 --
As Of 

Options Compensation

Name Options Value

Lars Ekman

 0 0

Randall Woods

 0 0

Peter Slover

 0 0

Allison Hulme

 0 0

Iain Mant

 0 0

John Geltosky

 0 0

James Heppell

 0 0

Noah Knauf

 0 0

William Rohn

 0 0

Amit Sobti

 0 0

Insider Trading

» Full list on Insider Trading
Search Stocks